文献速递腹部技术与安全US

对比增强超声在肝细胞癌诊断及局部治疗疗效评估中的应用

Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies.
PubMed 文献 · Abdom Radiol (NY) · 2021-04-07

本文综述了超声及对比增强超声(CEUS)在肝细胞癌(HCC)筛查、病灶表征及局部治疗疗效评估中的作用。CEUS 可实时引导治疗,并在检测残留肿瘤活性或复发方面优于增强 CT 和 MRI,能更早识别需再治疗的患者。

要点

  • CEUS 可用于高危人群 HCC 病灶表征,标准参照 ACR LI-RADS。
  • CEUS 实时引导局部治疗,并评估肿瘤反应。
  • CEUS 检测残留或复发优于增强 CT/MRI,可更早识别再治疗需求。

核心结论

  • CEUS 在 HCC 诊断和局部治疗疗效评估中具有重要价值,尤其在早期检测残留肿瘤活性或复发方面优于增强 CT 和 MRI。

研究设计与样本

  • 本文为综述,检索范围与纳入文献未在摘要中报告。

诊断标准与关键数值

  • CEUS 标准化标准由美国放射学会肝脏影像报告和数据系统(LI-RADS)建立,用于高危人群局灶性肝脏病灶表征。

临床应用与阅片要点

  • CEUS 可提供实时治疗引导,并提高检测残留肿瘤活性或复发的诊断性能,有助于更早识别需再治疗的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Hepatocellular carcinoma (HCC) is a global problem constituting the second leading cause of cancer deaths worldwide, thereby necessitating an accurate and cost-effective solution for managing care. Ultrasound is well poised to address this need due to its low cost, portability, safety, and excellent temporal resolution. The role of ultrasound for HCC screening has been well established and supported by multiple international guidelines. Similarly, contrast-enhanced ultrasound (CEUS) can be used for the characterization of focal liver lesions in high-risk populations, and standardized criteria for CEUS have been established by the American College of Radiology Liver Imaging Reporting & Data System (LI-RADS). Following HCC identification, CEUS can also be highly beneficial in treatment planning, delivery, and monitoring HCC response to locoregional therapies. Specific advantages of CEUS include providing real-time treatment guidance and improved diagnostic performance for the detection of residual tumor viability or recurrence, thereby identifying patients in need of retreatment substantially earlier than contrast-enhanced CT and MRI. This review provides a primer on ultrasound and CEUS for the screening and characterization of HCC, with an emphasis on assessing tumor response to locoregional therapies.

来源:Abdom Radiol (NY),查看原文。版权归原作者所有。

引用

  1. Eisenbrey JR, Gabriel H, Savsani E, et al. Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies. Abdom Radiol (NY). 2021. PMID: 33825927. doi:10.1007/s00261-021-03059-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。